Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-180M | $-158M | $-132M | -57.5% | - | -6.0% |
| 2024 | $0M | $-193M | $-168M | $-135M | -38.4% | - | 23.9% |
| 2023 | $0M | $-164M | $-136M | $-85M | -24.5% | - | 17.3% |
| 2022 | $0M | $-130M | $-116M | $-123M | -18.1% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 0 |
| Operating Revenue | 0 |
| Operating Expense | 180.89 |
| Research And Development | 148.02 |
| Selling General And Administration | 32.86 |
| Total Expenses | 180.89 |
| Operating Income | -180.89 |
| Total Operating Income As Reported | -180.89 |
| EBITDA | -180.47 |
| Normalized EBITDA | -180.47 |
| EBIT | -180.89 |
| Interest Income | 16.38 |
| Net Interest Income | 16.38 |
| Interest Income Non Operating | 16.38 |
| Net Non Operating Interest Income Expense | 16.38 |
| Pretax Income | -164.51 |
| Tax Provision | -6.16 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -158.35 |
| Net Income From Continuing And Discontinued Operation | -158.35 |
| Net Income From Continuing Operation Net Minority Interest | -158.35 |
| Net Income | -158.35 |
| Net Income Common Stockholders | -158.35 |
| Net Income Including Noncontrolling Interests | -158.35 |
| Normalized Income | -158.35 |
| Diluted NI Availto Com Stockholders | -158.35 |
| Basic Average Shares | - |
| Diluted Average Shares | - |
| Reconciled Depreciation | 0.42 |
| General And Administrative Expense | 32.86 |
| Other Gand A | 32.86 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Atea Pharmaceuticals, Inc.this co. | AVIR | $354M | -2.23 | 1.28 | -57.5% | -1.43 |
| Perspective Therapeutics, Inc. | CATX | $371M | -3.59 | 1.79 | -49.8% | -3.41 |
| Puma Biotechnology, Inc. | PBYI | $357M | 11.47 | 2.74 | 23.9% | 6.67 |
| REGENXBIO Inc. | RGNX | $356M | -1.83 | 3.46 | -188.7% | -2.96 |
| Greenwich LifeSciences, Inc. | GLSI |
| - |
| - |
| - |
| - |
| $347M |
| -21.99 |
| 136.99 |
| -623.1% |
| - |
| Larimar Therapeutics, Inc. | LRMR | $342M | - | 4.38 | -212.2% | - |
| Enanta Pharmaceuticals, Inc. | ENTA | $341M | -4.17 | 5.27 | -126.5% | -5.14 |
| Verastem, Inc. | VSTM | $339M | -1.62 | 5.93 | -366.2% | -1.07 |
| Simulations Plus, Inc. | SLP | $336M | -5.20 | 2.70 | -51.9% | 20.82 |
| Peer Median | - | -3.59 | 3.92 | -157.6% | -2.01 | |